Tags Archives: cardiogenic shock

Perfusfind S.L.

Abstract Beside the tremendous developments in cardiac surgical procedures, the use of cardiopulmonary bypass (CPB) remains the gold standard to perform cardiac surgery but is associated with detrimental effects (e.g...

Perfusfind S.L.

Abstract Complexity and a certain level of uncertainty are inherent to the clinical scenarios faced by the treating teams, often inundated with exhaustive details. Disease arises from a multitude of..

Perfusfind S.L.

Abstract Purpose Venoarterial extracorporeal membrane oxygenation (V-A ECMO) can be used to support severely ill patients with cardiogenic shock. While age is commonly used in patient selection, little is known..

Perfusfind S.L.

Abstract Background: VA-ECMO with concomitant Impella support (ECpella) is an emerging treatment modality for cardiogenic shock (CS). Survival outcomes by CS etiology with ECpella support have not been well-described. Methods: This study..

Perfusfind S.L.

Abstract Mechanical circulatory support (MCS) is an emerging therapy for acute heart failure (AHF) or cardiogenic shock (CS) patients unresponsive to medicinal treatment. In China, common treatments using short-term MCS..

Perfusfind S.L.

Abstract BACKGROUND: Although venoarterial extracorporeal membrane oxygenation (VA-ECMO) is beneficial for the treatment of profound cardiogenic shock, peripheral VA-ECMO cannulation can increase left ventricular afterload, thus compromising myocardial recovery. We..

Perfusfind S.L.

Abstract BACKGROUND Extracorporeal life support (ECLS) is increasingly used in the treatment of infarct-related cardiogenic shock despite a lack of evidence regarding its effect on mortality. METHODS In this multicenter..

Perfusfind S.L.

Abstract The use of intra-aortic balloon pump (IABP) has decreased in recent years due to negative outcome studies in cardiogenic shock complicating acute myocardial infarction, despite its favorable adverse-event profile...

Perfusfind S.L.

Abstract Background Myocardial injury-related cardiogenic shock (MICS) is significantly associated with poor outcomes in patients after cardiac surgery. Herein, we aimed to investigate the risk factor for postoperative MICS. Methods..

Perfusfind S.L.

Abstract Background Venoarterial  (VA-ECMO) is increasingly used  with  despite the lack of evidence from adequately powered . Three trials reported so far were underpowered to detect a survival benefit; we therefore conducted an individual..

Perfusfind S.L.

Abstract In patients with acute MI complicated by cardiogenic shock (AMICS) who are slated to undergo early revascularization, routine use of extracorporeal membrane oxygenation (ECMO) doesn’t reduce 30-day mortality. The..

Perfusfind S.L.

Abstract Background Venoarterial  (VA-ECMO) is increasingly used  with  despite the lack of evidence from adequately powered . Three trials reported so far were underpowered to detect a survival benefit; we therefore conducted an individual..

Perfusfind S.L.

Abstract There are minimal data on the use of venoarterial extracorporeal membrane life support (VA-ECLS) in adult congenital heart disease (ACHD) patients presenting with cardiogenic shock (CS). This study sought..

Perfusfind S.L.

Abstract Mixed cardiogenic-septic shock (MS), defined as the combination of cardiogenic (CS) and septic (SS) shock, is often encountered in cardiac intensive care units. Herein, the authors compared the impact of..

Perfusfind S.L.

Abstract Background The mortality rate for a patient with a refractory cardiogenic shock on venoarterial (VA) extracorporeal membrane oxygenation (ECMO) remains high, and hyperoxia might worsen this prognosis. The objective..

Perfusfind S.L.

Abstract Background: Exposure to hyperoxia, a high arterial partial pressure of oxygen (PaO2), may be associated with worse outcomes in patients receiving extracorporeal membrane oxygenator (ECMO) support. We examined hyperoxia in..

Perfusfind S.L.

Abstract Purpose: Veno‑arterial (VA) extracorporeal membrane oxygenation (ECMO) can be used to restore organ perfusionin patients with cardiogenic shock until native heart recovery occurs. It may be challenging, however, to..

Perfusfind S.L.

Abstract Aims Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is currently one of the most used devices in refractory cardiogenic shock. However, there is a lack of evidence on how to set..

Perfusfind S.L.

Abstract The time between onset of cardiogenic shock and initiation of mechanical circulatory support is inversely related to patient survival as delays in transporting patients to the operating room (OR)..

Perfusfind S.L.

Abstract In patients in cardiogenic shock (CS), mechanical circulatory support (MCS) may improve systemic perfusion without increasing myocardial work. Restoration of oxygen delivery with reduced myocardial oxygen demand favors myocardial..

Perfusfind S.L.

Abstract Background: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used for circulatory support in cardiogenic shock patients, although the evidence supporting its use in this context remains insufficient. The aim..

Perfusfind S.L.

Abstract Background and purpose Extracorporeal membrane oxygenation (ECMO) continues to play an essential role in organ support in cardiogenic shock or acute respiratory distress syndrome and bridging to transplantation. The..

Perfusfind S.L.

Abstract The recent widespread availability and use of mechanical circulatory support is transforming the management and outcomes of cardiogenic shock (CS). Clinical decision-making regarding the optimization of therapies for patients with..

Perfusfind S.L.

Abstract Background Shock severity predicts mortality in patients with cardiogenic shock (CS). We evaluated the association between pre-cannulation Society for Cardiovascular Angiography and Interventions (SCAI) shock classification and mortality among..

Perfusfind S.L.

Abstract Background: The mortality rate for a patient with a refractory cardiogenic shock on venoarterial (VA) extracorporealmembrane oxygenation (ECMO) remains high, and hyperoxia might worsen this prognosis. The objective of..

Perfusfind S.L.

Abstract Selecting patients most likely to benefit from venoarterial extracorporeal membrane oxygenation (V-A ECMO) to treat refractory drug-induced cardiovascular shock remains a difficult challenge for physicians. This study reported short-term..

Perfusfind S.L.

Abstract Venoarterial extracorporeal membrane oxygenation (V-A ECMO) is increasingly used in cardiogenic shock for rapid stabilization and bridging towards recovery, long-term mechanical circulatory support or transplant. Although technological advances have..

Perfusfind S.L.

Abstract The use of temporary mechanical circulatory support in cardiogenic shock has increased dramatically despite a lack of randomized controlled trials or evidence guiding clinical decision-making. Recommendations from professional societies..

Perfusfind S.L.

Abstract Purpose of review  Cardiogenic shock is a condition that is characterized by end-organ hypoperfusion secondary to reduced cardiac output, and is associated with substantial mortality. The mainstay of therapy..

Perfusfind S.L.

Abstract Purpose Venoarterial  (VA ECMO) effectively supports refractory  (rCS), and sustains macro- and . We investigated the respective impact of increasing VA ECMO flow or  dose on microcirculation in stabilized VA ECMO–treated patients with..